Date:10/7/2010

ance with medication for 75% of the dosing time points and had no major protocol violations.  Last Observation Carried Forward (LOCF), a method in which the last results before a subject drops out of the trial are carried forward to the end of the trial, was used in the ITT population when data were missing due to circumstances such as loss to follow-up.  The trial was conducted at 34 sites in the U.S. and 23 sites in India.  The final patient numbers were 172 in the drug arm and 184 in the placebo arm (ITT), and 85 in the drug arm and 119 in the placebo arm (PP).  A total of 102 patients were enrolled at U.S. sites, and 254 patients were enrolled at India sites.  The trial was initially powered by design to detect a reduction in HbA1c of 0.5%, but the variance in HbA1c at each time point was smaller than the original design assumption, enabling a smaller change in HbA1c to be detected with statistical significance.  Secondary endpoints included glucose measures, insulin measures, lipid profiles and changes in body weight.Table 1.  Reduction in HbA1c Over TimePatient population2 months6 months10 monthsU.S. PP-0.4*  (n=51)

-0.6*  (n=29)

-1.1*  (n=20)U.S. ITT LOCF-0.3* (n=100)

-0.3* (n=101)

-0.4* (n=101)India PP-0.1 (n=150)

0.0 (n=117)

-0.2 (n=72)India ITT LOCF-0.2 (n=253)

-0.1 (n=254)

-0.2* (n=254)Global PP-0.2 (n=201)

-0.2* (n=146)

-0.4* (n=92)Global ITT LOCF-0.2* (n=353)

-0.2* (n=355)

-0.2* (n=355)Global ITT (7.5<HbA1c<9.0)-0.3 (n=175)

0.1 (n=134)

-0.5* (n=92)PP = Per-Protocol; ITT = Intent-to-Treat; LOCF = Last Observation Carried Forward* p<0.05; all other figures do not have statistical significanceAbout SpherixSpherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research.  The Company now leverages its scientific and technical expertise and experience th
'/>"/>

SOURCE Spherix Incorporated Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. Spherix Announces Second Quarter 2010 Financial Results
2. Spherix Announces the Closing of $6.3 Million Registered Direct Offering
3. Spherix Announces Results of Annual Shareholders Meeting
4. Spherix Incorporated Announces Annual Shareholders Meeting Date
5. Spherix Incorporated Appoints Dr. Ram Nimmagudda As Director of New Business Development
6. Spherix Incorporated to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
7. Spherix Reports Second Quarter 2009 Earnings
8. Spherix Announces Termination of Arla License Agreement
9. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
10. Spherix Regains Full NASDAQ Compliance
11. Spherix to Exhibit at the BIO 2009 International Convention